Avalyn Pharma Inc. Common Stock (AVLN) Stock Score, Valuation & Financial Research

Avalyn Pharma Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AVLN

Avalyn Pharma Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 25.43. These figures are a research snapshot, not a buy or sell recommendation.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Avalyn Pharma develops inhaled medicines for rare respiratory diseases. Its June 2026 report states that no products were approved for sale and that it had not generated product-sales revenue. The lead programs include inhaled pirfenidone and inhaled nintedanib; their clinical progress is not a commercial-sales forecast. Research should compare planned trial spending with available cash, marketable securities and financing obligations. Management's projected cash runway depends on operating assumptions and can change as trial costs or timelines change. IPO proceeds and borrowing provide financing rather than earned revenue. Licensing and device arrangements also include potential milestones or royalties that affect future economics. A zero operating-revenue figure should therefore be interpreted in the context of a development-stage company, not silently replaced with another issuer's sales history or a mature-company growth estimate.

Products and services

  • The company is developing a pipeline of inhaled therapies, including AP01, designed to deliver established antifibrotic medicines directly to the lungs to treat pulmonary fibrosis.

Brands and product families

  • AP01 — Lead inhaled antifibrotic candidate for pulmonary fibrosis. Source

Customer types

Patients with pulmonary fibrosis and other rare respiratory diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business strengths to evaluate

  • Focus on inhaled delivery of established medicines to improve tolerability Source

Business risks and research considerations

  • Clinical and regulatory outcomes are uncertain Source
  • Trial spending, financing and licensing obligations Source

Sources: Avalyn Pharma June 30, 2026 Form 10-Q: pipeline and liquidity · AP01

Company research refreshed 2026-10-14. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AVLN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 25.43
Market capitalization:
1.13B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -85.2M
Free cash flow:
USD -81.83M
Cash:
USD 264.2M
Total debt:
USD 17.11M
EPS:
USD -2.04

What stands out

  • Free cash flow is USD -81.83M, negative for the stored period.
  • The balance sheet shows USD 264.2M of cash versus USD 17.11M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 247.09M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AVLN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AVLN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AVLN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AVLN to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of AVLN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research AVLN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.